L-M Hütter-Krönke

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Despite a growing number of new molecular targets, allogeneic hematopoietic cell transplantation remains the most relevant treatment for adverse risk AML. In order to balance a low therapyrelated mortality with high anti-leukemic efficacy relying on the GvL effect, Schmid et al. introduced a sequential therapy approach consisting of cytoreductive(More)
  • 1